Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep;10(3):146–157.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Mark J. Hamblin et al. Licensee Master Publishing Group

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

C57/BL6 mice were treated once daily with lovastatin 20 mg/kg by oral gavage one day prior to bleomycin lung injury (0.025 U/20g). A, Bronchoalveolar lavage at day 8, demonstrated significant differences between lovastatin and placebo treatment groups (n=3 in each group). Lovastatin treated mice had a markedly increased number of macrophages (p=0.002) and a statistically significant decrease in lymphocytes (p=0.01); B, The percentage of fibrocytes (CD45+/collagen+ cells) from whole lung lysates harvested at day 8 were also significantly decreased in lovastatin treated mice (p=0.001); C, Lovastatin treated mice demonstrated decreased histologic lung damage on hematoxylin and eosin stain with a decrease in collagen staining on Masson’s Trichrome Stain at day 14.